Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With Fibromyalgia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04322812
Recruitment Status : Recruiting
First Posted : March 26, 2020
Last Update Posted : July 15, 2020
Sponsor:
Collaborator:
Multi Radiance Medical
Information provided by (Responsible Party):
Ernesto Cesar Pinto Leal Junior, University of Nove de Julho

Brief Summary:
Fibromyalgia (FM) syndrome is defined by the American College of Rheumatology (ACR), as a chronic widespread pain and tenderness in at least eleven of eighteen specific tender points. Despite the increased understanding about FM, there is currently no cure for this syndrome and the treatment aims to provide symptomatic relief and improvement of physical capacities to perform daily tasks and quality of life. Evidence has suggest that photobiomodulation therapy (PBMT) can be used as monotherapy or as a supplementary treatment to other therapeutic procedures in patients with FM. However, the lack of consensus regarding therapeutic protocols hinders multicenter comparisons of the many clinical trials published. Further studies are needed to establish ideal parameters of PBMT to be used as a therapeutic tool in the management of fibromyalgia. Therefore, the aim of this project is to investigate the effectiveness of PBMT combined with static magnetic fields (sMF) in pain relief in patients with fibromyalgia.

Condition or disease Intervention/treatment Phase
Fibromyalgia Device: Active PBMT Device: Placebo PBMT Not Applicable

Detailed Description:

To achieve the proposed objectives it will be performed a randomized, triple-blind, placebo-controlled trial, with voluntary patients with fibromyalgia. Ninety patients will be randomly allocated to two treatment groups: 1. Active PBMT (MR5™ ACTIV PRO LaserShower) or Placebo PBMT (MR5™ ACTIV PRO LaserShower). The patients will be treated by a blinded therapist.

The patients randomly allocated to the different groups will be subjected to treatment 3 times a week, total of 9 sessions (with approximately 48 hours between each session), a total of 3 weeks of treatment.

The clinical outcomes will be obtained at the stabilization phase, baseline, end of treatment and 30 days after the conclusion of treatment.

The data will be collected by a blinded assessor.

Statistical analyzis:

  • The primary statistical method to analyze the primary endpoint will be Fisher's Exact Test to compare the proportion of success between the test (Active PBMT) and the control procedure (Placebo PBMT) groups, considering that randomization has been diligently conducted and important covariates between the two groups are well balanced. Statistical significance is set at p < 0.05.
  • Unpaired T test will be applied to analyze pain intensity through EVA. Mean and individual subject changes in VAS ratings across and between all study evaluation time-points, within and between procedure groups considering that randomization has been diligently conducted and important covariates between the two groups are well balanced. Statistical significance is set at p<0.05.
  • For patient satisfaction, measured through a Likert Scale, the data will be reduced to the nominal level by combining all agree and disagree responses into two categories of "accept" and "reject". Differences in satisfaction with Study Outcome Ratings between procedure groups at both evaluated time-points, and any change between. The chi-square, will be used after this transformation. Statistical significance is set at p<0.05.

The investigators will analyze: degree of pain rating (tender point count), pain intensity, patient satisfaction and adverse events

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: A researcher will program the device (placebo or PMBT) and will be instructed not to inform the patients or other researchers as to the type of treatment (PMBT or placebo). Therefore, the researcher responsible for the treatment, the investigator and the outcome assessor will be blinded to the type of treatment being administered to the patients. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (placebo or PBMT).
Primary Purpose: Treatment
Official Title: Evaluation of the Effects of Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) on Temporary Pain Relief in Fibromyalgia Patients: a Randomized Placebo-controlled Trial
Actual Study Start Date : March 31, 2020
Estimated Primary Completion Date : July 15, 2020
Estimated Study Completion Date : August 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fibromyalgia

Arm Intervention/treatment
Active Comparator: Active PBMT
Active PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
Device: Active PBMT
The Active PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA) will be used. The ACTIV PRO emits 30mW of 905nm, 300mW of 850nm, 200mW of 660nm and 0mW of 455nm light via an electric diode energy source. PBMT will be applied using the direct contact method with light pressure on the skin. The PBMT application time will be 120 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according widespread pain index [WPI] ), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 60 Joules (J) per region. The total dose might vary between patients and each session.

Placebo Comparator: Placebo PBMT
Placebo PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
Device: Placebo PBMT
The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The 660nm light via an electric diode energy source with outputs to >1% to appear like the active comparator. PBMT will be applied using the direct contact method with light pressure on the skin. The placebo PBMT application time will be 115 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according WPI), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 0 Joules (J) per region. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).




Primary Outcome Measures :
  1. Degree of pain rating - change of TCP (tender point count) [ Time Frame: 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment. ]
    Reduction of the tender point count (TCP) where they have experienced pain as reported on Fibromyalgia Impact Questionnaire (FIQ).


Secondary Outcome Measures :
  1. Pain intensity - VAS [ Time Frame: 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment. ]
    Pain intensity will be measured by 0-100 standardized Visual Analog Scale (VAS).

  2. Patient satisfaction - Likert Scale [ Time Frame: 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment. ]
    Patient satisfaction will be measured by 1-item Likert Scale. The scale uses the following responses: very satisfied = 4; somewhat satisfied = 3; not very satisfied = 2; not at all satisfied =1. Highest scores indicates better satisfaction.

  3. Adverse events [ Time Frame: 3 weeks (end of treatment) and 4 weeks after the conclusion of the treatment. ]
    Adverse events will be measured by report.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • being female;
  • age between 30 and 55 years;
  • have an ovulatory cycle;
  • height between 1.50m and 1.80m, body mass between 50 and 80 kg and BMI in the range of > or = to 18.5 kg/ m2;
  • present a diagnosis of fibromyalgia and meet the current criteria of the American College of Rheumatology;
  • had symptoms of fibromyalgia greater than 3 months;
  • Widespread Pain Index (WPI) score > or = to 9, Visual Analogue Scale score > or = to 50 Fibromyalgia Impact Questionnaire score > or = to 50
  • is not pregnant;
  • not having diabetes mellitus and uncontrolled blood pressure;
  • not having psychiatric illness or having malignant tumors;
  • did not present dengue, Zika or Chikungunya in the last year;
  • not to be hypersensitive to light;
  • cognitive level enough to understand the procedures and follow the guidelines;
  • consent to participate in the study and sign the consent form.

Exclusion Criteria:

  • arthritis, chronic fatigue syndrome, lupus, auto-immune diseases;
  • cognitive changes;
  • people who perform some exercise;
  • having a pacemaker;
  • people under the age of 30 and more than 55 years;
  • injuries in the last 6 months;
  • not attend for more than two consecutive sessions;
  • at any time and for any reason expressing an intention to leave the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04322812


Contacts
Layout table for location contacts
Contact: Ernesto Cesar Pinto Leal Junior, PhD +55 11 33859134 ernesto.leal.junior@gmail.com

Locations
Layout table for location information
Brazil
Laboratory of Phototherapy and Innovative Technologies in Health Recruiting
São Paulo, Brazil, 01504-001
Contact: Ernesto Cesar Pinto Leal Junior, PhD    +55 11 33859134      
Sponsors and Collaborators
University of Nove de Julho
Multi Radiance Medical
Investigators
Layout table for investigator information
Principal Investigator: Ernesto Cesar Pinto Leal Junior, PhD University of Nove de Julho
Layout table for additonal information
Responsible Party: Ernesto Cesar Pinto Leal Junior, Full professor, University of Nove de Julho
ClinicalTrials.gov Identifier: NCT04322812    
Other Study ID Numbers: 2.732.062
First Posted: March 26, 2020    Key Record Dates
Last Update Posted: July 15, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Ernesto Cesar Pinto Leal Junior, University of Nove de Julho:
Photobiomodulation Therapy
Low-level Laser Therapy
Fibromyalgia
Pain intensity
Additional relevant MeSH terms:
Layout table for MeSH terms
Fibromyalgia
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases